RxDoctor Payments Data

Thomas Ingarra, MD

Family Medicine · Kingston, NYNPI 1760572747

Payments from drug & device makers

$2,138in general payments, 2019–2025

Across 97 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$776
  • AbbVie$352
  • GSK$234
  • Lilly USA, LLC$201
  • Boehringer Ingelheim$182
  • Novo Nordisk$115
  • plus $278 from 7 others

What the payments were for

  • Food & beverage$2,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,138 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$8,960
Medicare patients
25
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$75,896
EliquisApixaban62$65,816
OzempicSemaglutide46$41,491
Tresiba Flextouch U-100Insulin Degludec37$34,396
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$30,663
XareltoRivaroxaban19$28,411
VraylarCariprazine Hcl14$25,833
FarxigaDapagliflozin Propanediol18$23,751
RybelsusSemaglutide18$20,615
LinzessLinaclotide34$19,423
GlyxambiEmpagliflozin/Linagliptin19$17,464
MounjaroTirzepatide12$16,218
TradjentaLinagliptin18$14,441
TrulicityDulaglutide13$13,901
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$182$107,801104 claims
PfizerEliquis$109$65,81662 claims
Novo NordiskOzempic, Rybelsus$115$62,10664 claims
AstraZenecaBreztri Aerosphere, Farxiga$776$54,41459 claims
AbbVieVraylar, Linzess$352$45,25648 claims
Lilly USA, LLCMounjaro, Trulicity$201$30,12025 claims
Johnson & JohnsonXarelto$35$28,41119 claims
GSKTrelegy Ellipta$234$11,72817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →